23 results on '"Arnalich Fernández, Francisco"'
Search Results
2. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry
- Author
-
Casas-Rojo, José-Manuel, Antón-Santos, Juan-Miguel, Millán-Núñez-Cortés, Jesús, Gómez-Huelgas, Ricardo, Ramos-Rincón, José-Manuel, Rubio-Rivas, Manuel, Corrales-González, Miguel-Ángel, Fernández-Madera-Martínez, Maria-Rosa, Beato-Pérez, José-Luis, Arnalich-Fernández, Francisco, Gállego-Lezaun, Cristina, Pérez-Martínez, Pablo, Molinos-Castro, Sonia, Tung-Chen, Yale, Madrazo, Manuel, Méndez-Bailón, Manuel, Monge-Monge, Daniel, García-García, Gema-María, García-Fenoll, Rosa, Gilabert, Noemí, Fuerte-Martínez, Rebeca, Contreras-Sánchez, Marta, Rhyman, Nicolás, Peris-García, Jorge, and Lumbreras-Bermejo, Carlos
- Published
- 2023
- Full Text
- View/download PDF
3. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
- Author
-
Núñez López, Concepción, González, Juan Manuel, Arizaga Lobeto, Natalia, Pérez Hidalgo, Natalia, Castiñeiras Ortega, Maria, Garcia-Pando, Consuelo Rodrigo, Pérez-Blanco, Verónica, García-Vaz, Claudia, García Rodríguez, Julio, Romero Gómez, María Pilar, Arnalich Fernández, Francisco, de Miguel Buckley, Rosa, Díaz-Menéndez, Marta, Arribas, Jose R., and González de Abreu, Juan Manuel
- Published
- 2023
- Full Text
- View/download PDF
4. Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study
- Author
-
Pina Belmonte, Adela, primary, Madrazo, Manuel, additional, Piles, Laura, additional, Rubio-Rivas, Manuel, additional, de Jorge Huerta, Lucía, additional, Gómez Antúnez, María, additional, López Caleya, Juan Francisco, additional, Arnalich Fernández, Francisco, additional, Gericó-Aseguinolaza, Martin, additional, Pesqueira Fontan, Paula Maria, additional, Rhyman, Nicolás, additional, Prieto Dehesa, Marina, additional, Romero Cabrera, Juan Luis, additional, García García, Gema María, additional, García-Casasola, Gonzalo, additional, Labirua-Iturburu Ruiz, Ane, additional, Carrasco-Sánchez, Francisco Javier, additional, Martínez Hernández, Sara, additional, Pascual Pérez, Maria de los Reyes, additional, López Castro, José, additional, Serrano Carrillo de Albornoz, José Luis, additional, Varona, José F., additional, Gómez-Huelgas, Ricardo, additional, Antón-Santos, Juan-Miguel, additional, and Lumbreras-Bermejo, Carlos, additional
- Published
- 2024
- Full Text
- View/download PDF
5. WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales
- Author
-
Rubio-Rivas, Manuel, Mora-Luján, José María, Formiga, Francesc, Arévalo-Cañas, Coral, Lebrón Ramos, Juan Manuel, Villalba García, María Victoria, Fonseca Aizpuru, Eva Mª, Díez-Manglano, Jesús, Arnalich Fernández, Francisco, Romero Cabrera, Juan Luis, García García, Gema María, Pesqueira Fontan, Paula M., Vargas Núñez, Juan Antonio, Freire Castro, Santiago Jesús, Loureiro Amigo, José, Pascual Pérez, Maria de los Reyes, Alcalá Pedrajas, José N., Encinas-Sánchez, Daniel, Mella Pérez, Carmen, Ena, Javier, Gracia Gutiérrez, Anyuli, Esteban Giner, María José, Varona, José F., Millán Núñez-Cortés, Jesús, and Casas-Rojo, José-Manuel
- Published
- 2022
- Full Text
- View/download PDF
6. Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model
- Author
-
Abrego-Vaca, Luis F., Andreu-Arnanz, Ana, Arce-García, Octavio A., Bajo-González, Marta, Borque-Sanz, Pablo, Cózar-Llistó, Alberto, Del Hoyo-Cuenda, Beatriz, Gamboa-Osorio, Alejandra, García-Sánchez, Isabel, López-Cisneros, Óscar A., Merino-Ortiz, Borja, Riera-González, Elisa, Rey-García, Jimena, Sánchez-Díaz, Cristina, Starita-Fajardo, Grisell, Suárez-Carantoña, Cecilia, Zhilina, Svetlana Zhilina, Martínez-Lacalzada, Miguel, Viteri-Noël, Adrián, Manzano, Luis, Fabregate, Martin, Rubio-Rivas, Manuel, Luis García, Sara, Arnalich-Fernández, Francisco, Beato-Pérez, José Luis, Vargas-Núñez, Juan Antonio, Calvo-Manuel, Elpidio, Espiño-Álvarez, Alexia Constanza, Freire-Castro, Santiago J., Loureiro-Amigo, Jose, Pesqueira Fontan, Paula Maria, Pina, Adela, Álvarez Suárez, Ana María, Silva-Asiain, Andrea, García-López, Beatriz, Luque del Pino, Jairo, Sanz-Cánovas, Jaime, Chazarra-Pérez, Paloma, García-García, Gema María, Núñez-Cortés, Jesús Millán, Casas-Rojo, José Manuel, and Gómez-Huelgas, Ricardo
- Published
- 2021
- Full Text
- View/download PDF
7. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
- Author
-
Bendala Estrada, Alejandro David, Calderón Parra, Jorge, Fernández Carracedo, Eduardo, Muiño Míguez, Antonio, Ramos Martínez, Antonio, Muñez Rubio, Elena, Rubio-Rivas, Manuel, Agudo, Paloma, Arnalich Fernández, Francisco, Estrada Perez, Vicente, Taboada Martínez, María Luisa, Crestelo Vieitez, Anxela, Pesqueira Fontan, Paula Maria, Bustamante, Marta, Freire, Santiago J., Oriol-Bermúdez, Isabel, Artero, Arturo, Olalla Sierra, Julián, Areses Manrique, María, Carrasco-Sánchez, H. Francisco Javier, Vento, Vanessa Carolina, García García, Gema María, Cubero-Morais, Pablo, Casas-Rojo, José-Manuel, and Núñez-Cortés, Jesús Millán
- Published
- 2021
- Full Text
- View/download PDF
8. Impacto de los días transcurridos desde el comienzo de los síntomas hasta la hospitalización en la mortalidad intrahospitalaria por COVID-19: el tiempo importa
- Author
-
Maestro de la Calle, Guillermo, primary, Reyne, Ana García, additional, Lora-Tamayo, Jaime, additional, Míguez, Antonio Muiño, additional, Arnalich-Fernández, Francisco, additional, Luis Beato Pérez, José, additional, Núñez, Juan Antonio Vargas, additional, Martínez, María Aranzazu Caudevilla, additional, Rivera, Nicolás Alcalá, additional, García, Eva Orviz, additional, Moreno, Beatriz Sánchez, additional, Castro, Santiago J. Freire, additional, Rhyman, Nicolás, additional, Fontán, Paula María Pesqueira, additional, Piles, Laura, additional, Caleya, Juan Francisco López, additional, Villarejo, María Esther Fraile, additional, Jiménez-García, Nicolás, additional, Boixeda, Ramón, additional, Noya, Amara González, additional, Gutiérrez, Anyuli Gracia, additional, Ángel Martín Oterino, José, additional, Huelgas, Ricardo Gómez, additional, Santos, Juan Miguel Antón, additional, and Bermejo, Carlos Lumbreras, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Prone Position in COVID-19 Patients With Severe Acute Respiratory Distress Syndrome Receiving Conventional Oxygen Therapy: A Retrospective Study
- Author
-
Loureiro-Amigo, Jose, Suárez-Carantoña, Cecilia, Oriol, Isabel, Sánchez-Díaz, Cristina, Coloma-Conde, Ana, Manzano-Espinosa, Luis, Rubio-Rivas, Manuel, Otero-Perpiñá, Barbara, Ferreiro-Mazón Jenaro, María Mercedes, Coduras-Erdozain, Ainara, Garcia-Klepzig, José Luis, Vargas-Parra, Derly, Pesqueira-Fontán, Paula M, Fiteni-Mera, Isabel, García-García, Gema María, Jiménez-Torres, José, Rodríguez-Cortés, Pablo, Costo-Muriel, Clara, Arnalich-Fernández, Francisco, Artero, Arturo, Carrasco-Sánchez, Francisco Javier, Escobar-Sevilla, Joaquín, Alcalá-Pedrajas, José Nicolás, Gómez-Huelgas, Ricardo, Ramos-Rincón, José-Manuel, and SEMI-COVID-19 Network
- Subjects
Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,MEDLINE ,Retrospective cohort study ,Acute respiratory distress ,Prone position ,Oxygen therapy ,Emergency medicine ,medicine ,business - Published
- 2022
10. Influencia de la historia de tabaquismo en la evolución de la hospitalización en pacientes COVID-19 positivos: datos del registro SEMI-COVID-19
- Author
-
Navas Alcántara, María Sierra, primary, Montero Rivas, Lorena, additional, Guisado Espartero, María Esther, additional, Rubio-Rivas, Manuel, additional, Ayuso García, Blanca, additional, Moreno Martinez, Francisco, additional, Ausín García, Cristina, additional, Taboada Martínez, María Luisa, additional, Arnalich Fernández, Francisco, additional, Martínez Murgui, Raúl, additional, Molinos Castro, Sonia, additional, Ramos Muñoz, Maria Esther, additional, Fernández-Garcés, Mar, additional, Carreño Hernandez, Mari Cruz, additional, García García, Gema María, additional, Vázquez Piqueras, Nuria, additional, Abadía-Otero, Jesica, additional, Lajara Villar, Lourdes, additional, Salazar Monteiro, Cristina, additional, Pascual Pérez, María de los Reyes, additional, Perez-Martin, Santiago, additional, Collado-Aliaga, Javier, additional, Antón-Santos, Juan-Miguel, additional, and Lumbreras-Bermejo, Carlos, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Influence of smoking history on the evolution of hospitalized in COVID-19 positive patients: Results from the SEMI-COVID-19 registry
- Author
-
Navas Alcántara, María Sierra, primary, Montero Rivas, Lorena, additional, Guisado Espartero, María Esther, additional, Rubio-Rivas, Manuel, additional, Ayuso García, Blanca, additional, Moreno Martinez, Francisco, additional, Ausín García, Cristina, additional, Taboada Martínez, María Luisa, additional, Arnalich Fernández, Francisco, additional, Martínez Murgui, Raúl, additional, Molinos Castro, Sonia, additional, Ramos Muñoz, Maria Esther, additional, Fernández-Garcés, Mar, additional, Carreño Hernandez, Mari Cruz, additional, García García, Gema María, additional, Vázquez Piqueras, Nuria, additional, Abadía-Otero, Jesica, additional, Lajara Villar, Lourdes, additional, Salazar Monteiro, Cristina, additional, Pascual Pérez, María de los Reyes, additional, Perez-Martin, Santiago, additional, Collado-Aliaga, Javier, additional, Antón-Santos, Juan-Miguel, additional, and Lumbreras-Bermejo, Carlos, additional
- Published
- 2022
- Full Text
- View/download PDF
12. C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19
- Author
-
Giner Galvañ, Vicente, Pomares Gómez, Francisco, Quesada, José, Rubio Rivas, Manuel, Tejada Montes, Javier, Baltasar Corral, Jesús, Taboada-Martínez, María Luisa, Sánchez Mesa, Blanca, Arnalich Fernández, Francisco, Corral Beamonte, Esther del, López Sampalo, Almudena, Pesqueira Fontán, Paula, Fernández Garcés, Mar, Gómez Huelgas, Ricardo, Ramos Rincón, José, and SEMI-COVID-19 Network
- Subjects
COVID-19 ,serum albumin ,C-reactive protein ,prognosis ,syndemic ,comorbidity ,Comorbiditat ,Medicine (miscellaneous) ,Comorbidity ,General Biochemistry, Genetics and Molecular Biology - Abstract
(1) Background: C-reactive protein (CRP) and albumin are inflammatory markers. We analyzed the prognostic capacity of serum albumin (SA) and CRP for an outcome comprising mortality, length of stay, ICU admission, and non-invasive mechanical ventilation in hospitalized COVID-19 patients. (2) Methods: We conducted a retrospective cohort study based on the Spanish national SEMI-COVID-19 Registry. Two multivariate logistic models were adjusted for SA, CRP, and their combination. Training and testing samples were used to validate the models. (3) Results: The outcome was present in 41.1% of the 3471 participants, who had lower SA (mean [SD], 3.5 [0.6] g/dL vs. 3.8 [0.5] g/dL; p < 0.001) and higher CRP (108.9 [96.5] mg/L vs. 70.6 [70.3] mg/L; p < 0.001). In the adjusted multivariate model, both were associated with poorer evolution: SA, OR 0.674 (95% CI, 0.551–0.826; p < 0.001); CRP, OR 1.002 (95% CI, 1.001–1.004; p = 0.003). The CRP/SA model had a similar predictive capacity (honest AUC, 0.8135 [0.7865–0.8405]), with a continuously increasing risk and cutoff value of 25 showing the highest predictive capacity (OR, 1.470; 95% CI, 1.188–1.819; p < 0.001). (4) Conclusions: SA and CRP are good independent predictors of patients hospitalized with COVID-19. For the CRP/SA ratio value, 25 is the cutoff for poor clinical course.
- Published
- 2022
13. Importancia de la asociación entre la enfermedad de Kikuchi y el lupus erimatoso sistémico
- Author
-
Carrasco-Molina, Sergio, primary, Álvarez-Troncoso, Jorge, additional, Robles-Marhuenda, Ángel, additional, and Arnalich-Fernández, Francisco, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry
- Author
-
Ramos-Rincón, José Manuel, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manuel, Martos-Pérez, Francisco, Lalueza-Blanco, Antonio, Moragón-Ledesma, Sergio, Fonseca-Aizpuru, Eva-María, García-García, Gema-María, Beato-Pérez, José-Luis, Josa-Laorden, Claudia, Arnalich-Fernández, Francisco, Molinos-Castro, Sonia, Torres‑Peña, J.D., Artero, Arturo, Vargas-Núñez, Juan-Antonio, Méndez-Bailón, Manuel, Loureiro-Amigo, Jose, Hernández-Garrido, María-Soledad, Peris-García, Jorge, López-Reboiro, Manuel-Lorenzo, Barón-Franco, Bosco, Casas-Rojo, José Manuel, Gómez-Huelgas, Ricardo, and SEMI‐COVID‐19 Network
- Subjects
SARS-CoV-2 ,Spain ,Minority groups ,COVID-19 ,General Medicine ,Grups ètnics ,ethnic groups ,minority groups ,migrants ,Ethnic groups ,Migrants - Abstract
(1) Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26–2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
- Published
- 2022
15. WHO Ordinal Scale and Inflammation Risk Categories in COVID-19
- Author
-
Rubio-Rivas, Manuel, Mora Luján, José María, Formiga Pérez, Francesc, Arévalo-Cañas, Coral, Lebrón Ramos, Juan Manuel, Villalba García, María Victoria, Fonseca Aizpuru, Eva Maria, Díez Manglano, Jesús, Arnalich Fernández, Francisco, Romero Cabrera, Juan Luis, García García, Gema María, Pesqueira Fontan, Paula María, Vargas Núñez, Juan Antonio, Freire Castro, Santiago Jesús, Loureiro Amigo, José, Pascual Pérez, Maria de los Reyes, Alcalá Pedrajas, José Nicolás, Encinas-Sánchez, Daniel, Mella Pérez, Carmen, Ena, Javier, Gracia Gutiérrez, Anyuli, Esteban Giner, María José, Varona, José F., Millán Núñez-Cortés, Jesús, and Casas-Rojo, José Manuel
- Subjects
Inflammation ,Pronòstic mèdic ,Mortalitat ,COVID-19 ,Mortality ,Prognosis ,Inflamació - Abstract
Background: The WHO ordinal severity scale has been used to predict mortality and guide trials in COVID-19. However, it has its limitations. Objective The present study aims to compare three classificatory and predictive models: the WHO ordinal severity scale, the model based on inflammation grades, and the hybrid model. Design Retrospective cohort study with patient data collected and followed up from March 1, 2020, to May 1, 2021, from the nationwide SEMI-COVID-19 Registry. The primary study outcome was in-hospital mortality. As this was a hospital-based study, the patients included corresponded to categories 3 to 7 of the WHO ordinal scale. Categories 6 and 7 were grouped in the same category. Key Results A total of 17,225 patients were included in the study. Patients classified as high risk in each of the WHO categories according to the degree of inflammation were as follows: 63.8% vs. 79.9% vs. 90.2% vs. 95.1% (p
- Published
- 2022
16. Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19
- Author
-
Lavilla Olleros, Cristina, Ausín García, Cristina, Bendala Estrada, Alejandro David, Muñoz, Ana, Wikman Jogersen, Philip Erick, Fernández Cruz, Ana, Giner Galvañ, Vicente, Vargas, Juan Antonio, Seguí Ripoll, José Miguel, Rubio Rivas, Manuel, Miranda Godoy, Rodrigo, Mérida Rodrigo, Luis, Fonseca Aizpuru, Eva, Arnalich Fernández, Francisco, Artero, Arturo, Loureiro Amigo, Jose, García García, Gema María, Corral Gudino, Luis, Jiménez Torres, Jose, Casas Rojo, José Manuel, Millán Núñez-Cortés, Jesús, and On Behalf of the SEMI-COVID-19 Network
- Subjects
RNA viruses ,Male ,Viral Diseases ,Pulmonology ,Coronaviruses ,Epidemiology ,Steroid Therapy ,Medical Conditions ,Adrenal Cortex Hormones ,Medicine and Health Sciences ,Hospital Mortality ,Registries ,Pathology and laboratory medicine ,Aged, 80 and over ,Multidisciplinary ,Pharmaceutics ,Adrenocortical hormones ,Age Factors ,Medical microbiology ,Middle Aged ,Hospitals ,Glucocorticoid Therapy ,Intensive Care Units ,Infectious Diseases ,Treatment Outcome ,Viruses ,Medicine ,Female ,SARS CoV 2 ,Pathogens ,Research Article ,Adult ,SARS coronavirus ,Death Rates ,Science ,Corticosteroid Therapy ,Microbiology ,Drug Administration Schedule ,Drug Therapy ,Population Metrics ,Sepsis ,Humans ,Epidemiologia ,Aged ,Population Biology ,SARS-CoV-2 ,Organisms ,Viral pathogens ,Biology and Life Sciences ,COVID-19 ,Covid 19 ,Pneumonia ,Corticosteroides ,Survival Analysis ,Microbial pathogens ,COVID-19 Drug Treatment ,Health Care ,Health Care Facilities ,Spain ,Prednisone - Abstract
Objective To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Methods Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Results Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59–79] vs 73 years [IQR 61–83]; p < .001). Radiological and analytical findings showed a higher use of megadoses therapy among patients with an interstitial infiltrate and elevated inflammatory markers associated with COVID-19. In the univariate study it appears that steroid use is associated with increased mortality (OR 2.07 95% CI 1.91–2.24 p < .001) and megadose use with increased survival (OR 0.84 95% CI 0.75–0.96, p 0.011), but when adjusting for possible confounding factors, it is observed that the use of megadoses is also associated with higher mortality (OR 1.54, 95% CI 1.32–1.80; p < .001). There is no difference between megadoses and low-dose (p .298). Although, there are differences in the use of megadoses versus low-dose in terms of complications, mainly infectious, with fewer pneumonias and sepsis in the megadoses group (OR 0.82 95% CI 0.71–0.95; p < .001 and OR 0.80 95% CI 0.65–0.97; p < .001) respectively. Conclusion There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.
- Published
- 2022
17. Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model
- Author
-
Martínez-Lacalzada, Miguel, primary, Viteri-Noël, Adrián, additional, Manzano, Luis, additional, Fabregate, Martin, additional, Rubio-Rivas, Manuel, additional, Luis García, Sara, additional, Arnalich-Fernández, Francisco, additional, Beato-Pérez, José Luis, additional, Vargas-Núñez, Juan Antonio, additional, Calvo-Manuel, Elpidio, additional, Espiño-Álvarez, Alexia Constanza, additional, Freire-Castro, Santiago J., additional, Loureiro-Amigo, Jose, additional, Pesqueira Fontan, Paula Maria, additional, Pina, Adela, additional, Álvarez Suárez, Ana María, additional, Silva-Asiain, Andrea, additional, García-López, Beatriz, additional, Luque del Pino, Jairo, additional, Sanz-Cánovas, Jaime, additional, Chazarra-Pérez, Paloma, additional, García-García, Gema María, additional, Núñez-Cortés, Jesús Millán, additional, Casas-Rojo, José Manuel, additional, Gómez-Huelgas, Ricardo, additional, Abrego-Vaca, Luis F., additional, Andreu-Arnanz, Ana, additional, Arce-García, Octavio A., additional, Bajo-González, Marta, additional, Borque-Sanz, Pablo, additional, Cózar-Llistó, Alberto, additional, Del Hoyo-Cuenda, Beatriz, additional, Gamboa-Osorio, Alejandra, additional, García-Sánchez, Isabel, additional, López-Cisneros, Óscar A., additional, Merino-Ortiz, Borja, additional, Riera-González, Elisa, additional, Rey-García, Jimena, additional, Sánchez-Díaz, Cristina, additional, Starita-Fajardo, Grisell, additional, Suárez-Carantoña, Cecilia, additional, and Zhilina, Svetlana Zhilina, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Screening Protocol and Prevalence of Venous Thromboembolic Disease in Hospitalized Patients With COVID‐19
- Author
-
Álvarez‐Troncoso, Jorge, primary, Ramos‐Ruperto, Luis, additional, Fernández‐Cidón, Pelayo, additional, Trigo‐Esteban, Elena, additional, Tung‐Chen, Yale, additional, Busca‐Arenzana, Carmen, additional, Quintana‐Díaz, Manuel, additional, Buño‐Soto, Antonio, additional, Arnalich‐Fernández, Francisco, additional, and Fernández‐Capitán, Carmen, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Screening Protocol and Prevalence of Venous Thromboembolic Disease in Hospitalized Patients With COVID‐19.
- Author
-
Álvarez‐Troncoso, Jorge, Ramos‐Ruperto, Luis, Fernández‐Cidón, Pelayo, Trigo‐Esteban, Elena, Tung‐Chen, Yale, Busca‐Arenzana, Carmen, Quintana‐Díaz, Manuel, Buño‐Soto, Antonio, Arnalich‐Fernández, Francisco, and Fernández‐Capitán, Carmen
- Subjects
COVID-19 ,MEDICAL screening ,HOSPITAL patients ,VENOUS thrombosis ,CYTOKINE release syndrome - Abstract
Background: SARS‐CoV‐2 disease (COVID‐19) induces endothelial damage and sustained hypoxia and facilitates immobilization as factors of hypercoagulability. Objectives: The objective of our study was to assess the prevalence of venous thromboembolic disease (VTD) in COVID‐19 patients and the usefulness of VTD screening based on age‐adjusted D‐dimer and point‐of‐care ultrasound (POCUS). Patients/Methods: We conducted a single cohort, prospective observational study in 102 consecutive hospitalized patients. Results: A total of 102 POCUS and 39 pulmonary computed tomography angiography (PCTA) were performed diagnosing 27 VTD (26.5%): 17 deep vein thrombosis (DVT) (16.6% positive POCUS) and 18 pulmonary embolism (PE) (46.2% positive PCTA). COVID‐19 patients with VTD were older (P <.030), had higher D‐dimer (P <.001), higher International Society on Thrombosis and Hemostasis score (P <.001), and higher mortality (P =.025). However, there were no differences in inflammatory laboratory parameters neither in the cytokine storm syndrome (CSS) development. The ROC curve for D‐dimer showed an AUC of 0.91. We have evidenced that patients with D‐dimer between 2000 and 6000 ng/mL could benefit from a screening strategy with POCUS given the high sensitivity and specificity of the test. Furthermore, patients with D‐dimer ≥6000 ng/mL should undergo POCUS and PCTA to rule out DVT and PE, respectively. Conclusions: In our cohort, 26.5% of the patients presented VTD. Screening strategy based on age‐adjusted D‐dimer and POCUS proved high sensitivity and specificity. Future trials focused on screening strategies are necessary to early detect the presence of DVT and PE and determine thromboprophylaxis strategies in patients with COVID‐19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19.
- Author
-
Giner-Galvañ, Vicente, Pomares-Gómez, Francisco José, Quesada, José Antonio, Rubio-Rivas, Manuel, Tejada-Montes, Javier, Baltasar-Corral, Jesús, Taboada-Martínez, María Luisa, Sánchez-Mesa, Blanca, Arnalich-Fernández, Francisco, Del Corral-Beamonte, Esther, López-Sampalo, Almudena, Pesqueira-Fontán, Paula María, Fernández-Garcés, Mar, Gómez-Huelgas, Ricardo, and Ramos-Rincón, José Manuel
- Subjects
BLOOD proteins ,SERUM albumin ,COVID-19 ,C-reactive protein ,PROGNOSIS - Abstract
(1) Background: C-reactive protein (CRP) and albumin are inflammatory markers. We analyzed the prognostic capacity of serum albumin (SA) and CRP for an outcome comprising mortality, length of stay, ICU admission, and non-invasive mechanical ventilation in hospitalized COVID-19 patients. (2) Methods: We conducted a retrospective cohort study based on the Spanish national SEMI-COVID-19 Registry. Two multivariate logistic models were adjusted for SA, CRP, and their combination. Training and testing samples were used to validate the models. (3) Results: The outcome was present in 41.1% of the 3471 participants, who had lower SA (mean [SD], 3.5 [0.6] g/dL vs. 3.8 [0.5] g/dL; p < 0.001) and higher CRP (108.9 [96.5] mg/L vs. 70.6 [70.3] mg/L; p < 0.001). In the adjusted multivariate model, both were associated with poorer evolution: SA, OR 0.674 (95% CI, 0.551–0.826; p < 0.001); CRP, OR 1.002 (95% CI, 1.001–1.004; p = 0.003). The CRP/SA model had a similar predictive capacity (honest AUC, 0.8135 [0.7865–0.8405]), with a continuously increasing risk and cutoff value of 25 showing the highest predictive capacity (OR, 1.470; 95% CI, 1.188–1.819; p < 0.001). (4) Conclusions: SA and CRP are good independent predictors of patients hospitalized with COVID-19. For the CRP/SA ratio value, 25 is the cutoff for poor clinical course. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Mecanismos moleculares de resistencia a cisplatino activados por consumo de tabaco en cáncer de pulmón
- Author
-
Extremera Mazuela, María, Montiel López, Carmen, Arnalich Fernández, Francisco, and UAM. Departamento de Farmacología
- Subjects
Medicina ,Farmacología ,Fisiología - Abstract
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Farmacología. Fecha de Lectura: 02-12-2022, Varios ensayos clínicos han demostrado peor evolución clínica y menor respuesta a la quimioterapia (quimiorresistencia), incluyendo a los derivados del platino, de los pacientes con cáncer de pulmón de células no pequeñas (NSCLC) fumadores frente a no fumadores. Datos preliminares in vitro de nuestro laboratorio han revelado que la nicotina del tabaco, y su nitrosamina derivada NNK, a través de la activación de receptores nicotínicos para la acetilcolina del subtipo α7 (α7-nAChRs) expresados en las células epiteliales y tumorales de pulmón, están implicadas en la anterior quimiorresistencia al interferir con el efecto citotóxico de cisplatino a nivel de la apoptosis. Sin embargo, se desconocen los mecanismos moleculares puestos en marcha por el α7-nAChR para interferir con el efecto proapoptótico de cisplatino, o si dicha resistencia a cisplatino mediada por el anterior subtipo de receptor se reproduce in vivo. También permanece por dilucidar si otros subtipos del nAChR, distintos al α7-nAChR, contribuyen a la anterior quimiorresistencia, así como si los hallazgos in vitro e in vivo relativos al mecanismo molecular implicado en la quimiorresistencia pueden ser corroborados en la clínica. En base a lo anterior, esta Tesis Doctoral tiene como OBJETIVO GENERAL tratar de resolver las cuatro incógnitas planteadas. Con este propósito hemos realizado experimentos in vitro utilizando diversas variantes de la línea celular humana de adenocarcinoma de pulmón A549 [salvaje, o con distintas subunidades del nAChR (α3, α5, β4, α7) silenciadas con siRNAs específicos (knockdown) o mediante CRISPR-Cas9 (knockout)], junto a experimentos in vivo en un modelo xenográfico murino de NSCLC, combinados con experimentos en tumores primarios de 107 pacientes con NSCLC, tanto fumadores (n = 59) como no fumadores (n = 48). En los experimentos in vitro e in vivo se ha empleado cisplatino como agente quimioterápico, y en el conjunto de la Tesis una combinación de técnicas que incluyen la PCR cuantitativa, citometría de flujo, microarrays proteicos, inmunoblot, inmunohistoquímica y ensayos de tumorogenicidad. Nuestros principales hallazgos son los siguientes: (i) se identifican las proteínas quinasas y factores de transcripción cuya actividad es desregulada por nicotina, a través del α7-nAChR, promoviendo la supervivencia celular y, por tanto, contrarrestando el efecto citotóxico de cisplatino; (ii) se corrobora in vivo el papel determinante del α7-nAChR en la resistencia a cisplatino inducida por nicotina en el tumor xenográfico NSCLC del ratón; (iii) se constata, también in vivo, que en la resistencia a cisplatino inducida por nicotina subyace un aumento de expresión de proteínas antiapoptóticas y disminución de las proapoptóticas en el tumor xenográfico; (iv) la anterior alteración del patrón de expresión génica de proteínas reguladoras de apoptosis inducida por nicotina in vivo es corroborada en tumores primarios NSCLC de fumadores frente a no fumadores; (v) se demuestra que otros subtipos de nAChRs, además del α7-nAChR, contribuyen a la anterior quimiorresistencia. En conjunto, nuestros resultados in vitro, in vivo y en tumores primarios de pacientes con NSCLC revelan el mecanismo molecular que subyace en la resistencia a la quimioterapia inducida por el consumo de tabaco en este tipo de tumor. A través de este mecanismo, los componentes del tabaco nicotina/NNK, activando α7-nAChRs y otros subtipos de nAChRs, alterarían la capacidad apoptótica celular generando un “estado antiapoptótico” en el tumor que lo haría refractario al efecto citotóxico de la quimioterapia. En base a nuestros hallazgos, la presente Tesis aporta argumentos científicos sólidos para concienciar a médicos, pacientes, y población en general, acerca de que el consumo de tabaco no solo es la principal causa prevenible de cáncer y muerte por cáncer, sino también del previsible fracaso terapéutico y peor evolución que este hábito puede ocasionaren en los pacientes con NSCLC y otros tumores asociados al tabaquismo, La presente Tesis Doctoral ha sido financiada por el Ministerio de Ciencia e Innovación de España bajo el proyecto SAF2017SAF2017-8268982689-R
- Published
- 2022
22. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry.
- Author
-
Ramos-Rincon JM, Cobos-Palacios L, López-Sampalo A, Ricci M, Rubio-Rivas M, Martos-Pérez F, Lalueza-Blanco A, Moragón-Ledesma S, Fonseca-Aizpuru EM, García-García GM, Beato-Perez JL, Josa-Laorden C, Arnalich-Fernández F, Molinos-Castro S, Torres-Peña JD, Artero A, Vargas-Núñez JA, Mendez-Bailon M, Loureiro-Amigo J, Hernández-Garrido MS, Peris-García J, López-Reboiro ML, Barón-Franco B, Casas-Rojo JM, Gómez-Huelgas R, and On Behalf Of The Semi-Covid-Network
- Abstract
(1) Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5−58.9) to 57.1 (44.1−67.1) vs. 71.5 (59.5−81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10−0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17−1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26−2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21−1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
- Published
- 2022
- Full Text
- View/download PDF
23. Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19.
- Author
-
Lavilla Olleros C, Ausín García C, Bendala Estrada AD, Muñoz A, Wikman Jogersen PE, Fernández Cruz A, Giner Galvañ V, Vargas JA, Seguí Ripoll JM, Rubio-Rivas M, Miranda Godoy R, Mérida Rodrigo L, Fonseca Aizpuru E, Arnalich Fernández F, Artero A, Loureiro Amigo J, García García GM, Corral Gudino L, Jiménez Torres J, Casas-Rojo JM, and Millán Núñez-Cortés J
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, COVID-19 mortality, COVID-19 virology, Drug Administration Schedule, Female, Hospital Mortality trends, Humans, Male, Middle Aged, SARS-CoV-2 growth & development, Sepsis epidemiology, Sepsis mortality, Sepsis virology, Spain epidemiology, Survival Analysis, Treatment Outcome, Adrenal Cortex Hormones therapeutic use, COVID-19 epidemiology, Prednisone therapeutic use, Registries, SARS-CoV-2 pathogenicity, Sepsis drug therapy, COVID-19 Drug Treatment
- Abstract
Objective: To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses., Methods: Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses., Results: Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p < .001). Radiological and analytical findings showed a higher use of megadoses therapy among patients with an interstitial infiltrate and elevated inflammatory markers associated with COVID-19. In the univariate study it appears that steroid use is associated with increased mortality (OR 2.07 95% CI 1.91-2.24 p < .001) and megadose use with increased survival (OR 0.84 95% CI 0.75-0.96, p 0.011), but when adjusting for possible confounding factors, it is observed that the use of megadoses is also associated with higher mortality (OR 1.54, 95% CI 1.32-1.80; p < .001). There is no difference between megadoses and low-dose (p .298). Although, there are differences in the use of megadoses versus low-dose in terms of complications, mainly infectious, with fewer pneumonias and sepsis in the megadoses group (OR 0.82 95% CI 0.71-0.95; p < .001 and OR 0.80 95% CI 0.65-0.97; p < .001) respectively., Conclusion: There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.